Brexafemme Kit in 2026: What's Happening and What You Should Know

If you rely on Brexafemme Kit (Ibrexafungerp) to treat or prevent vaginal yeast infections, 2026 has been a difficult year. The medication remains temporarily unavailable, leaving patients searching for answers — and for alternatives.

This shortage update covers everything you need to know: the current status, why the shortage happened, what it costs, what new options are available, and how to find it when it comes back.

Is Brexafemme Kit Still in Shortage?

Yes. As of early 2026, Brexafemme Kit remains temporarily unavailable from the manufacturer. According to the American Society of Health-System Pharmacists (ASHP), Scynexis listed Brexafemme as temporarily unavailable with no estimated return date.

Key timeline events:

• June 2021: FDA approved Brexafemme for acute vulvovaginal candidiasis (VVC)
• November 2022: FDA approved second indication for reducing recurrent VVC (RVVC)
• 2024: FDA placed a clinical hold on Ibrexafungerp studies
• May 2025: FDA lifted the clinical hold
• November 2025: Scynexis completed the NDA transfer to GSK
• Early 2026: Drug remains temporarily unavailable; no confirmed return date

Why Is Brexafemme Kit Hard to Find?

The shortage stems from a combination of factors:

1. FDA clinical hold — A clinical hold on Ibrexafungerp studies disrupted the supply chain and commercial availability
2. Manufacturer transition — Scynexis, the original developer, has transferred the NDA to GSK. During this transition, manufacturing and distribution have been paused
3. No generic alternative — Without a generic version, there's no backup manufacturer to fill the gap
4. Limited prior inventory — Brexafemme was a relatively new, specialty medication, so pharmacies generally didn't carry large stockpiles

For a deeper explanation, see: Why Is Brexafemme Kit So Hard to Find?

How Much Does Brexafemme Kit Cost in 2026?

When Brexafemme Kit was commercially available, here's what patients could expect to pay:

• Cash price (without insurance): $450–$600 per treatment course
• With manufacturer copay card: As low as $30 for eligible commercially insured patients
• With insurance: Varies by plan; many required prior authorization or step therapy (trying Fluconazole first)
• GoodRx price: Approximately $550 with a GoodRx Gold coupon

Currently, since the drug is unavailable, these prices are historical. When Brexafemme Kit returns to market under GSK, pricing may change. For savings strategies, see: How to Save Money on Brexafemme Kit.

What New Options Are Available?

While waiting for Brexafemme Kit to return, patients have several treatment options:

For Acute Yeast Infections

• Fluconazole (Diflucan): Single 150 mg oral dose, generic, $3–$15. The most widely available first-line treatment
• Miconazole (Monistat): OTC topical treatment, $10–$20. Available in 1-day, 3-day, and 7-day options
• Clotrimazole: OTC topical treatment, $8–$15

For Recurrent Yeast Infections (RVVC)

• Oteseconazole (Vivjoa): The only other medication specifically FDA-approved for RVVC prevention. Prescription only, brand-name pricing
• Fluconazole maintenance: 150 mg weekly for 6 months (off-label but commonly used by gynecologists)

Read the full comparison: Alternatives to Brexafemme Kit.

How to Find Brexafemme Kit When It Returns

When GSK resumes distribution of Brexafemme Kit, here's how to be first in line:

1. Use Medfinder: Medfinder.com tracks pharmacy availability in real time — search for Brexafemme Kit and set up alerts
2. Keep your prescription active: Make sure your doctor's prescription is on file at your preferred pharmacy
3. Ask for a waitlist: Have your pharmacy add you to their notification list for when the medication is restocked
4. Check independent pharmacies: Specialty and independent pharmacies sometimes receive limited stock before large chains

For a detailed walkthrough, see: How to Find Brexafemme Kit in Stock Near You and How to Check If a Pharmacy Has Brexafemme Kit in Stock.

Final Thoughts

The Brexafemme Kit shortage has been a significant challenge for patients with vaginal yeast infections, particularly those with recurrent infections who don't respond well to Fluconazole. The positive developments — the lifted clinical hold and the completed NDA transfer to GSK — suggest that the medication may eventually return to market, but there's no confirmed timeline.

In the meantime, work with your healthcare provider to find the best alternative treatment plan. And use Medfinder to stay on top of availability changes as they happen.